Can engineered immune cells tame autoimmune anemia?

NCT ID NCT07748533

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental treatment called HY001N, a type of CAR-T cell therapy, in adults with autoimmune hemolytic anemia (AIHA) who have not improved after three or more standard treatments. The goal is to see if the therapy is safe and tolerable, and whether it can help restore normal red blood cell levels and reduce the disease's symptoms. Participants will receive the cell infusion and be monitored closely for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HY001N cell injection (CAR-T cell therapy)
What this could lead to
If successful, this could lead to a new treatment option for people with autoimmune hemolytic anemia who have not responded to standard therapies, potentially offering a durable remission.
What could go wrong
This is an early-phase trial with only 9 participants, so results may not apply broadly. CAR-T therapy carries risks of severe side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital

    RECRUITING

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.